Joyce O'Shaugnessy, MD, Texas Oncology

home / authors / joyce-oshaugnessy-md-texas-oncology

Articles

Updated Data for Metastatic HER2+ Breast Cancer

Updated Data for Metastatic HER2+ Breast Cancer

Ruth O'Regan, MD, University of Rochester Medical Center;Joyce O'Shaugnessy, MD, Texas Oncology;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Debu Tripathy, MD, MD Anderson Cancer Center
January 25th 2021

Read More

Prognostic Tools for Early-Stage HER2+ Breast Cancer

Prognostic Tools for Early-Stage HER2+ Breast Cancer

Ruth O'Regan, MD, University of Rochester Medical Center;Joyce O'Shaugnessy, MD, Texas Oncology;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Debu Tripathy, MD, MD Anderson Cancer Center
January 25th 2021

Read More

Current Treatment Landscape for HER2+ Breast Cancer

Current Treatment Landscape for HER2+ Breast Cancer

Ruth O'Regan, MD, University of Rochester Medical Center;Joyce O'Shaugnessy, MD, Texas Oncology;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Debu Tripathy, MD, MD Anderson Cancer Center
January 25th 2021

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data